Eosinophilic Asthma Market Summary

• The Eosinophilic Asthma Market size is anticipated to grow with a significant CAGR during the study period (2020-2034). 
• The Eosinophilic Asthma companies developing therapies include AstraZeneca, GlaxoSmithKline, Sanofi, Regeneron Pharmaceuticals, Teva Pharmaceuticals, Areteia Therapeutics, Chiesi Pharmaceuticals, Novartis, Knopp Biosciences, and others.

Eosinophilic Asthma Market and Epidemiology Analysis

• Eosinophilic asthma is a subtype of severe asthma characterized by elevated levels of eosinophils (a type of white blood cell) in the blood, sputum, or airway tissues.
• Globally, asthma affects more than 260 million people, according to the World Health Organization.
• In April 2024, AstraZeneca announced results of a study to evaluate the efficacy and safety of benralizumab administered subcutaneously in patient’s ≥ 6 to < 18 years of age with severe eosinophilic asthma, including a well-documented history of asthma exacerbations and uncontrolled asthma receiving high-dose inhaled corticosteroid (ICS) plus at least one additional controller medication.
• In February 2024, Areteia Therapeutics announced results of a Randomized, Double-blind, Placebo-controlled, and Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Dexpramipexole Administered Orally for 52 Weeks in Participants with Severe Eosinophilic Asthma.
• Approximately 5–10% of all asthma patients suffer from severe asthma, which often includes eosinophilic asthma as a major phenotype.
• Among severe asthma cases, around 40–60% are associated with eosinophilic inflammation, making it one of the most common inflammatory subtypes.
• Eosinophilic asthma is more commonly diagnosed in adults, especially in individuals aged 30–50 years, although it can occur at any age.
• Studies indicate that blood eosinophil levels ≥150–300 cells/µL are frequently used as a biomarker to identify eosinophilic asthma patients.
• In the United States, it is estimated that about 1–2 million patients have eosinophilic asthma.
• In the 7 Major Markets (7MM)—including the United States, Germany, France, Italy, Spain, United Kingdom, and Japan—the diagnosed prevalent population of severe eosinophilic asthma continues to increase due to improved diagnostic tools and awareness.

Factors affecting the Eosinophilic Asthma Market Growth

Increasing Prevalence of Eosinophilic Asthma

The growing global incidence of severe asthma, particularly eosinophilic subtypes, is a major market driver. Rising exposure to environmental pollutants and allergens is expanding the patient pool, thereby increasing demand for targeted therapies and long-term disease management solutions.

Advancements in Biologic Therapies

Innovative biologics developed by AstraZeneca, GlaxoSmithKline, and Sanofi are transforming treatment. These therapies improve outcomes by targeting specific inflammatory pathways, driving higher adoption and boosting overall market growth.

Rising Adoption of Precision Medicine

The shift toward personalized treatment based on biomarkers like eosinophil counts is enhancing therapeutic effectiveness. Precision medicine enables clinicians to tailor treatments, improving patient outcomes and increasing the uptake of advanced biologics in eosinophilic asthma care.

Improved Diagnostic Technologies

Advancements in diagnostic tools are enabling accurate identification of eosinophilic asthma patients. Enhanced testing methods support early diagnosis and appropriate therapy selection, contributing to increased treatment rates and driving the growth of the targeted therapeutics market.

Strong R&D and Pipeline Innovation

Continuous research and development activities are introducing novel therapies, including oral treatments. Companies such as Areteia Therapeutics are expanding the pipeline, creating new opportunities and strengthening the future outlook of the eosinophilic asthma market.

Increasing Healthcare Expenditure

Rising healthcare spending and improved reimbursement policies are enhancing patient access to expensive biologic treatments. Developed markets, in particular, are witnessing higher adoption rates due to favorable insurance coverage and better healthcare infrastructure.

Request a sample to unlock the CAGR for "Eosinophilic Asthma Market Forecast"

DelveInsight's "Eosinophilic Asthma Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Eosinophilic Asthma, historical and forecasted epidemiology as well as the Eosinophilic Asthma therapeutics market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Eosinophilic Asthma market report provides current treatment practices, emerging drugs, Eosinophilic Asthma market share of the individual therapies, current and forecasted Eosinophilic Asthma market Size from 2020 to 2034 segmented by seven major markets. The Report also covers current Eosinophilic Asthma treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Eosinophilic Asthma market.

Eosinophilic Asthma Disease Understanding:

Eosinophilic Asthma Overview

Eosinophilic asthma is a distinct inflammatory subtype of asthma characterized by elevated levels of eosinophils in the airways, blood, or sputum. It is commonly associated with Type 2 inflammation, driven by cytokines such as interleukin-5 (IL-5). This condition often presents with severe symptoms, frequent exacerbations, and persistent airway inflammation despite standard therapy. Unlike allergic asthma, eosinophilic asthma may develop later in life and is not always linked to common allergens. The disease burden is significant, often impacting lung function, quality of life, and increasing the risk of hospitalization.

Eosinophilic Asthma Diagnosis:

The diagnosis of eosinophilic asthma involves a combination of clinical evaluation and biomarker assessment. Physicians typically assess patient history, symptom severity, and frequency of exacerbations. Biomarkers play a crucial role, with blood eosinophil counts being the most widely used indicator. Additional diagnostic tools include fractional exhaled nitric oxide (FeNO) testing and sputum eosinophil analysis. These tests help identify underlying eosinophilic inflammation and differentiate this subtype from other forms of asthma. Early and accurate diagnosis is essential for guiding appropriate treatment strategies and improving patient outcomes.

Eosinophilic Asthma Treatment:

Treatment of eosinophilic asthma focuses on reducing inflammation, controlling symptoms, and preventing exacerbations. Standard therapies include inhaled corticosteroids and bronchodilators; however, many patients require advanced treatment options. Biologic therapies targeting specific inflammatory pathways, such as IL-4/IL-13, have significantly improved disease management. These targeted treatments help reduce eosinophil levels, decrease exacerbation rates, and improve lung function. A personalized treatment approach based on biomarker levels and disease severity is increasingly adopted to achieve optimal control and enhance the patient’s quality of life.

Eosinophilic Asthma Epidemiology 

The Eosinophilic Asthma epidemiology section provides insights about the historical and current Eosinophilic Asthma patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Eosinophilic Asthma market report also provides the diagnosed patient pool and their trends along with assumptions undertaken. 

Key Findings from Eosinophilic Asthma Epidemiological Analyses and Forecast

• In April 2024, AstraZeneca announced results of a study to evaluate the efficacy and safety of benralizumab administered subcutaneously in patient’s ≥ 6 to < 18 years of age with severe eosinophilic asthma, including a well-documented history of asthma exacerbations and uncontrolled asthma receiving high-dose inhaled corticosteroid (ICS) plus at least one additional controller medication.
• In February 2024, Areteia Therapeutics announced results of a Randomized, Double-blind, Placebo-controlled, and Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Dexpramipexole Administered Orally for 52 Weeks in Participants with Severe Eosinophilic Asthma.
• Approximately 5–10% of all asthma patients suffer from severe asthma, which often includes eosinophilic asthma as a major phenotype.
• Among severe asthma cases, around 40–60% are associated with eosinophilic inflammation, making it one of the most common inflammatory subtypes.
• Eosinophilic asthma is more commonly diagnosed in adults, especially in individuals aged 30–50 years, although it can occur at any age.
• Studies indicate that blood eosinophil levels ≥150–300 cells/µL are frequently used as a biomarker to identify eosinophilic asthma patients.
• In the United States, it is estimated that about 1–2 million patients have eosinophilic asthma.
• In the 7 Major Markets (7MM)—including the United States, Germany, France, Italy, Spain, United Kingdom, and Japan—the diagnosed prevalent population of severe eosinophilic asthma continues to increase due to improved diagnostic tools and awareness.

Country Wise- Eosinophilic Asthma Epidemiology

The Eosinophilic Asthma epidemiology segment also provides the Eosinophilic Asthma epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Eosinophilic Asthma Recent Developments

• In September 2025, Areteia Therapeutics announced positive Phase III results from the EXHALE-4 study, evaluating dexpramipexole as an oral add-on therapy for eosinophilic asthma. The findings support the drug's potential to improve outcomes in patients with this severe asthma subtype.

Eosinophilic Asthma Drug Chapters

The drug chapter segment of the Eosinophilic Asthma report encloses the detailed analysis of Eosinophilic Asthma marketed drugs and late-stage (Phase-III and Phase-II) Eosinophilic Asthma pipeline drugs. It also helps to understand the Eosinophilic Asthma clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. The Eosinophilic Asthma drugs market is expanding rapidly due to rising prevalence and advancements in targeted biologic therapies.

Eosinophilic Asthma Marketed Drugs:

Eosinophilic asthma treatment has significantly evolved with the introduction of targeted biologic therapies that address underlying Type 2 inflammation. Key marketed drugs include Mepolizumab, Reslizumab, and Benralizumab, which directly reduce eosinophil levels. Additionally, Dupilumab targets IL-4/IL-13 pathways, while Tezepelumab acts upstream in the inflammatory cascade. Omalizumab is also used in patients with overlapping allergic asthma. These therapies have improved disease control by reducing exacerbations, enhancing lung function, and minimizing dependence on systemic corticosteroids.

Eosinophilic Asthma Emerging Drugs:

The Eosinophilic Asthma pipeline for eosinophilic asthma is robust, focusing on novel targets and improved dosing convenience. Prominent emerging therapies include Depemokimab, which offers extended dosing intervals of up to six months, and Itepekimab, targeting upstream inflammatory pathways. Other candidates such as Astegolimab and Melrilimab are being evaluated in clinical trials. These emerging therapies aim to address unmet needs by improving efficacy, reducing treatment burden, and expanding options for patients who remain uncontrolled with existing biologics.

Eosinophilic Asthma Market Outlook

The Eosinophilic Asthma market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Eosinophilic Asthma market trends by analyzing the impact of current Eosinophilic Asthma therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of Eosinophilic Asthma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Eosinophilic Asthma market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Eosinophilic Asthma market in 7MM is expected to witness a major change in the study period 2020-2034.

The United States Eosinophilic Asthma Market Outlook

This section provides the total Eosinophilic Asthma market size and market size by therapies in the United States.

EU-5 Countries Eosinophilic Asthma Market Outlook

The total Eosinophilic Asthma market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.

Japan Eosinophilic Asthma Market Outlook

The total Eosinophilic Asthma market size and market size by therapies in Japan is also mentioned.

Eosinophilic Asthma Competitive Landscape

The eosinophilic asthma market is highly competitive and driven by innovation, with major pharmaceutical companies such as GlaxoSmithKline, AstraZeneca, Sanofi, Novartis, and Teva Pharmaceutical Industries dominating through their strong biologics portfolios targeting Type 2 inflammation. Competition is centered on developing next-generation therapies with improved efficacy, longer dosing intervals, and novel mechanisms of action, alongside strategic collaborations and co-development agreements to expand global reach. Additionally, the emergence of biotech firms and biosimilar manufacturers is intensifying pricing pressure and improving accessibility, while established players focus on lifecycle management and indication expansion to maintain market leadership.

Key Eosinophilic Asthma Companies

The Eosinophilic Asthma companies developing therapies include

• AstraZeneca,
• GlaxoSmithKline,
• Sanofi,
• Regeneron Pharmaceuticals,
• Teva Pharmaceuticals,
• Areteia Therapeutics,
• Chiesi Pharmaceuticals,
• Novartis,
• Knopp Biosciences, and others.

Eosinophilic Asthma Drugs Uptake

This section focuses on the rate of uptake of the potential Eosinophilic Asthma drugs recently launched in the Eosinophilic Asthma market or expected to get launched in the market during the study period 2020-2034. The analysis covers Eosinophilic Asthma market uptake by drugs; patient uptake by therapies; and sales of each drug.   

Eosinophilic Asthma Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Eosinophilic Asthma market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Eosinophilic Asthma Clinical Trials Activities

The Eosinophilic Asthma pipeline insights report provides insights into different Eosinophilic Asthma clinical trials within Phase II, and Phase III stage. It also analyses Eosinophilic Asthma key players involved in developing targeted therapeutics.

Eosinophilic Asthma Pipeline Development Activities

The Eosinophilic Asthma clinical trials analysis report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Eosinophilic Asthma emerging therapies.

Eosinophilic Asthma Market Access and Reimbursement

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

Latest KOL Views on Eosinophilic Asthma

To keep up with current Eosinophilic Asthma market trends, we take KOLs and SMEs ' opinion working in the Eosinophilic Asthma domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Eosinophilic Asthma market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Eosinophilic Asthma Competitive Intelligence Analysis

We perform Competitive and Eosinophilic Asthma Market Intelligence analysis of the Eosinophilic Asthma Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Eosinophilic Asthma Market Report

• The Eosinophilic Asthma Market report covers the descriptive overview of Eosinophilic Asthma, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
• Comprehensive insight has been provided into the Eosinophilic Asthma epidemiology and treatment in the 7MM
• Additionally, an all-inclusive account of both the current and emerging therapies for Eosinophilic Asthma is provided, along with the assessment of new therapies, which will have an impact on the current Eosinophilic Asthma treatment landscape
• A detailed review of the Eosinophilic Asthma market; historical and forecasted is included in the report, covering drug outreach in the 7MM
• The Eosinophilic Asthma Market report provides an edge while developing business strategies, by understanding trends shaping and driving the global Eosinophilic Asthma market

Eosinophilic Asthma Report Highlights

• In the coming years, the Eosinophilic Asthma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The Eosinophilic Asthma companies and academics are working to assess challenges and seek opportunities that could influence Eosinophilic Asthma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition      
• Major Eosinophilic Asthma players are involved in developing therapies for Eosinophilic Asthma. The launch of emerging therapies will significantly impact the Eosinophilic Asthma market
• A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Eosinophilic Asthma
• Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Eosinophilic Asthma Market Report Insights

• Eosinophilic Asthma Patient Population
• Eosinophilic Asthma Therapeutic Approaches
• Eosinophilic Asthma Pipeline Analysis
• Eosinophilic Asthma Market Size and Trends
• Eosinophilic Asthma Market Opportunities
• Impact of upcoming Eosinophilic Asthma Therapies

Eosinophilic Asthma Market Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Eosinophilic Asthma Epidemiology Segmentation
• Eosinophilic Asthma Market Key Cross Competition
• Highly AnalyzedEosinophilic Asthma Market
• Eosinophilic Asthma Drugs Uptake

Eosinophilic Asthma Market Report Assessment

• Current Eosinophilic Asthma Treatment Practices
• Eosinophilic Asthma Unmet Needs
• Eosinophilic Asthma Pipeline Product Profiles
• Eosinophilic Asthma Market Attractiveness
• Eosinophilic Asthma Market Drivers
• Eosinophilic Asthma Market Barriers

Key Questions Answered In The Eosinophilic Asthma Market Report:

Eosinophilic Asthma Market Insights:

• What was the Eosinophilic Asthma drug class share (%) distribution in 2020 and how it would look like in 2034?
• What would be the Eosinophilic Asthma total market size as well as market size by therapies across the 7MM during the forecast period (2020-2034)?
• What are the Eosinophilic Asthma key findings pertaining to the market across 7MM and which country will have the largest Eosinophilic Asthma market size during the forecast period (2020-2034)?
• At what CAGR, the Eosinophilic Asthma market is expected to grow by 7MM during the forecast period (2020-2034)?
• What would be the Eosinophilic Asthma market outlook across the 7MM during the forecast period (2020-2034)?
• What would be the Eosinophilic Asthma market growth till 2034, and what will be the resultant market Size in the year 2034?
• How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?

Eosinophilic Asthma Epidemiology Insights:

• What are the Eosinophilic Asthma risk, burden, and regional/ethnic differences of the Eosinophilic Asthma?
• What are the Eosinophilic Asthma key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What is the historical Eosinophilic Asthma patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Eosinophilic Asthma in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Eosinophilic Asthma?
• Out of all 7MM countries, which country would have the highest prevalent population of Eosinophilic Asthma during the forecast period (2020-2034)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2020-2034)?

Current Eosinophilic Asthma Treatment Scenario, Marketed Drugs and Emerging Therapies:

• What are the current options for the Eosinophilic Asthma treatment in addition to the approved therapies?
• What are the current treatment guidelines for the treatment of Eosinophilic Asthma in the USA, Europe, and Japan?
• What are the Eosinophilic Asthma marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
• How many Eosinophilic Asthma companies are developing therapies for the treatment of Eosinophilic Asthma?
• How many Eosinophilic Asthma therapies are in-development by each company for Eosinophilic Asthma treatment?
• How many are emerging therapies in mid-stage, and late stage of development for Eosinophilic Asthma treatment?
• What are the Eosinophilic Asthma key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Eosinophilic Asthma therapies?
• What are the Eosinophilic Asthma recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Eosinophilic Asthma and their status?
• What are the current challenges faced in drug development?
• What are the key designations that have been granted for the emerging therapies for Eosinophilic Asthma?
• What are the global historical and forecasted market of Eosinophilic Asthma?

Reasons to buy Eosinophilic Asthma Market Forecast Report

• The Eosinophilic Asthma market report will help in developing business strategies by understanding trends shaping and driving the Eosinophilic Asthma market
• To understand the future Eosinophilic Asthma market competition in the Eosinophilic Asthma market and Insightful review of the key market drivers and barriers
• Organize sales and marketing efforts by identifying the best opportunities for Eosinophilic Asthma in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
• Organize sales and marketing efforts by identifying the best opportunities for Eosinophilic Asthma market.
• To understand the future Eosinophilic Asthma market competition in the Eosinophilic Asthma market.